Abstract |
Therapeutic angiogenesis using angiogenic growth factors is expected to be a new treatment of patients with severe ischemic diseases. Indeed, human gene therapy for peripheral arterial disease(PAD) using VEGF gene demonstrated the beneficial effects. In contrast, we have reported the potent angiogenic activity of hepatocyte growth factor (HGF) in animal study and we planned gene therapy for ASO and Buerger disease using HGF gene (TREAT-HGF). In a prospective, open-labeled clinical trial, we investigated the safety and biological efficiency of this gene therapy in patients with peripheral arterial disease(PAD) who had failed conventional therapy.
|
Authors | Motokuni Aoki, Toshio Ogihara, Ryuichi Morishita |
Journal | Nihon rinsho. Japanese journal of clinical medicine
(Nihon Rinsho)
Vol. 60
Issue 9
Pg. 1845-55
(Sep 2002)
ISSN: 0047-1852 [Print] Japan |
PMID | 12233086
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Endothelial Growth Factors
- Intercellular Signaling Peptides and Proteins
- Lymphokines
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
- Hepatocyte Growth Factor
|
Topics |
- Arteriosclerosis Obliterans
(therapy)
- Clinical Trials as Topic
- Endothelial Growth Factors
(genetics)
- Genetic Therapy
(methods)
- Hepatocyte Growth Factor
(genetics)
- Humans
- Intercellular Signaling Peptides and Proteins
(genetics)
- Lymphokines
(genetics)
- Neovascularization, Physiologic
(genetics)
- Thromboangiitis Obliterans
(therapy)
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
|